AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other Events

ME Staff 8-k
-
0

AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other Events
Item 8.01. Other Events.

On September6, 2017, Amicus Therapeutics,Inc. (the “Company”) presented data related to its Fabry program at the 13thInternational Congress of Inborn Errors of Metabolism in Rio de Janeiro, Brazil. The posters presented are attached hereto as Exhibit99.1.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits: The ExhibitIndex annexed hereto is incorporated herein by reference.

Exhibit No.

Description

99.1

Amicus Therapeutics,Inc. Fabry program data posters presented at the 13thInternational Congress of Inborn Errors of Metabolism in Rio de Janeiro, Brazil


AMICUS THERAPEUTICS INC Exhibit
EX-99.1 2 a17-21323_1ex99d1.htm EX-99.1 Exhibit 99.1   638 Long-Term Migalastat Treatment Stabilizes Renal Function in Patients With Fabry Disease: Results From a Phase 3 Clinical Study (AT1001-041) Lourenço C1,…
To view the full exhibit click here

About AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD)

Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.

AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Recent Trading Information

AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) closed its last trading session down -0.01 at 14.07 with 2,101,020 shares trading hands.